Research
Hormonal
GLP-1RA treatment induces distinct molecular changes in skeletal muscle proteome (upregulation of mitochondrial proteins) compared to calorie restriction, despite similar weight loss and muscle mass changes.
This finding is primarily mechanistic and suggests GLP-1s may improve muscle metabolic efficiency (mitochondrial function) beyond just weight loss, though this does not currently translate to a specific user action beyond standard treatment.
GoodSupportsHIGH confidence
Interestingly, while atrophy is similar during immobilization, GLP-1 medicines have a distinct effect on the muscle proteome compared to calorie restriction.
Why this rating
Robust proteomic analysis (LC-MS/MS) with clear differential expression of mitochondrial proteins.
Source
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
Henning T. Langer et al. · Cell Reports Medicine · 2026
DOI 10.1016/j.xcrm.2026.102665
clinical_trial · n=10Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →